IMMUNOME INC (IMNM) Stock Analyst Ratings
NASDAQ:IMNM • US45257U1088
21.68 USD
-0.21 (-0.96%)
Last: Feb 27, 2026, 03:06 PM
ChartMill assigns a Buy % Consensus number of 85% to IMNM. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 35.14. This target is 62.1% above the current price.
- IMNM was analyzed by 19 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IMNM.
- In the previous month the buy percentage consensus was at a similar level.
- IMNM was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-12 | HC Wainwright & Co. | Initiate | Buy |
| 2026-01-15 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-12-16 | Lake Street | Maintains | Buy -> Buy |
| 2025-12-16 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-01 | Truist Securities | Initiate | Buy |
| 2025-11-17 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-09-22 | Goldman Sachs | Initiate | Buy |
| 2025-09-05 | Craig-Hallum | Initiate | Buy |
| 2025-08-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-08-22 | Evercore ISI Group | Initiate | Outperform |
| 2025-08-07 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-04-02 | Lake Street | Initiate | Buy |
| 2025-03-20 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-20 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-11 | LifeSci Capital | Initiate | Outperform |
| 2024-11-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-10-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2024-04-30 | JP Morgan | Initiate | Overweight |
| 2024-04-15 | Guggenheim | Initiate | Buy |
| 2024-04-01 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-12-19 | Wedbush | Initiate | Outperform |
| 2023-03-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-03-17 | Chardan Capital | Maintains | Buy |
IMMUNOME INC / IMNM FAQ
What is the average price target for IMMUNOME INC (IMNM) stock?
19 analysts have analysed IMNM and the average price target is 35.14 USD. This implies a price increase of 62.1% is expected in the next year compared to the current price of 21.68.
What is the consensus rating for IMNM stock?
The consensus rating for IMMUNOME INC (IMNM) is 85.2632 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for IMMUNOME INC stock?
The number of analysts covering IMMUNOME INC (IMNM) is 19.